The European Commission has approved olaparib as a single agent for the maintenance treatment of adult patients with advanced BRCA1/2-mutated germline and/or somatic high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.
Mihaela C. Cristea, MD, emphasizes the use of molecular testing over tumor testing in ovarian cancer.
Thanh H. Dellinger, MD, provides insight on the treatment of patients with newly diagnosed advanced ovarian cancer.
Mihaela C. Cristea, MD, discusses the impact of the SOLO-1 trial on current approaches to frontline maintenance therapy as well as the trials that are underway with niraparib, rucaparib, and the investigational PARP inhibitor veliparib.
The PARP inhibitor olaparib reduced the risk of disease progression or death by 38% versus chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA1/2-mutated ovarian cancer who received at least 2 prior lines of chemotherapy.
A chemotherapy-free doublet for platinum-sensitive recurrent ovarian cancer more than doubled progression-free survival as compared with single-agent PARP inhibitor.
Pre-Medicare-aged women with ovarian cancer were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis after passage of the Affordable Care Act than before.
Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.
Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.
Gottfried E. Konecny, MD, shares the known aspects of PARP inhibition in recurrent ovarian cancer.